| Title: | Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study |
| Authors: | Kato, Masaru Browse this author →KAKEN DB |
| Kaneko, Yuko Browse this author →KAKEN DB |
| Tanaka, Yoshiya Browse this author →KAKEN DB |
| Inoo, Masayuki Browse this author |
| Kobayashi-Haraoka, Hitomi Browse this author |
| Amano, Koichi Browse this author →KAKEN DB |
| Miyata, Masayuki Browse this author |
| Murakawa, Yohko Browse this author |
| Yasuoka, Hidekata Browse this author |
| Hirata, Shintaro Browse this author →KAKEN DB |
| Nagasawa, Hayato Browse this author →KAKEN DB |
| Tanaka, Eiichi Browse this author |
| Miyasaka, Nobuyuki Browse this author →KAKEN DB |
| Yamanaka, Hisashi Browse this author →KAKEN DB |
| Yamamoto, Kazuhiko Browse this author →KAKEN DB |
| Yokota, Isao Browse this author →KAKEN DB |
| Atsumi, Tatsuya Browse this author →KAKEN DB |
| Takeuchi, Tsutomu Browse this author →KAKEN DB |
| Keywords: | Monotherapy |
| prediction |
| remission |
| serum amyloid A |
| tocilizumab |
| Issue Date: | 7-Jun-2019 |
| Publisher: | Taylor & Francis |
| Journal Title: | Modern rheumatology |
| Volume: | 30 |
| Issue: | 3 |
| Start Page: | 442 |
| End Page: | 449 |
| Publisher DOI: | 10.1080/14397595.2019.1621026 |
| PMID: | 31106666 |
| Abstract: | Objectives: To identify predictive factors for remission by tocilizumab monotherapy in rheumatoid arthritis (RA) patients. Methods: This is a post hoc analysis of the SURPRISE study, a 2-year randomized, controlled study comparing the efficacy of tocilizumab with (ADD-ON) and without methotrexate (SWITCH). The primary endpoint was DAS28-ESR remission (<2.6) at week 24. The change in modified total Sharp score from baseline to week 52 (Delta mTSS/year) was also assessed as an endpoint. The effect of clinical parameters at baseline on remission was estimated by logistic regression analysis. Results: In SWITCH (n = 96), CRP, SAA, RF, and DAS28 at baseline showed predictive value for DAS28 remission in unadjusted analysis. Adjusted analysis confirmed SAA and DAS28 as predictive factors, with SAA having the highest value (ROC-AUC = 0.731). Furthermore, structural remission (Delta mTSS/year <= 0.5) rate was significantly higher in patients with SAA of < 50.0 mu g/mL than other patients. In contrast, in ADD-ON (n = 98), only DAS28 showed predictive value for DAS28 remission. In patients with SAA < 50.0 mu g/mL, both DAS28 remission and structural remission rate were comparable between SWITCH and ADD-ON. Conclusion: RA patients with low SAA levels at baseline may benefit similarly from tocilizumab with and without methotrexate. |
| Rights: | This is an Accepted Manuscript of an article published by Taylor & Francis in Modern rheumatology on 07 Jun 2019, available online:http://www.tandfonline.com/10.1080/14397595.2019.1621026. |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/81114 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
